← Home
Kyowa Kirin
-11.97%
Pharma / Pharma
Press Releases
| Date | Press release |
|---|---|
| 2025-04-03 19:14:00 | 35-year Industry-academic Partnership Yielding Groundbreaking Advances For Science And Patients Renews For Another Three Years Between La Jolla Institute For Immunology And Kyowa Kirin -agreement extends one of the world’s most enduring alliances for drug discovery- -landmark discoveries from partnership have led to novel drug candidates, including an immunotherapy for moderate to severe atopic dermatitis currently in phase iii clinical trials- - new focus on cell and gene therapies to accelerate novel treatments for patients with unmet medical needs - la jolla, calif. and princeton, n.j. |
| 2025-02-26 08:00:00 | Kyowa Kirin Announces Late-breaking Abstract Presentation At The American Academy Of Dermatology Annual Meeting 2025 Princeton, n.j. , feb. 26, 2025 /prnewswire/ -- kyowa kirin co., ltd. |
| 2025-01-30 05:05:00 | Kyowa Kirin And Swixx Biopharma Announce Expansion Of Access To Poteligeo® (mogamulizumab) For Adults Living With Mycosis Fungoides Or SÉzary Syndrome In Central And Eastern Europe Galashiels & marlow, england & baar, switzerland--(business wire)--kyowa kirin international (kki), a wholly owned subsidiary of kyowa kirin co. ltd., and swixx biopharma ag today announced that the croatian national health insurance fund (nhif) and the bulgarian ministry of health have both approved the reimbursement of poteligeo® (mogamulizumab) for adult patients with mycosis fungoides (mf), and sÉzary syndrome (ss). mf and ss are two subtypes of cutaneous t-cell lymphoma (ctcl), a rare form. |
| 2025-01-28 10:00:00 | Alphameld Corporation Expands Collaboration With Kyowa Kirin For Enterprise-wide Access To Drug Discovery Platform Longstanding relationship strengthens innovation, providing diverse stakeholders access to advanced ai-driven insights to accelerate therapeutic discovery and development longstanding relationship strengthens innovation, providing diverse stakeholders access to advanced ai-driven insights to accelerate therapeutic discovery and development |
| 2024-12-09 20:00:00 | Cimeio Therapeutics Announces Partnership With Kyowa Kirin To Develop Novel Cell Therapies Basel, switzerland--(business wire)--cimeio therapeutics announced today that it has entered a research collaboration with kyowa kirin co., ltd. (kyowa kirin) to develop a novel therapy for diseases with high unmet need. the partnership combines cimeio’s proprietary shielded-cell & immunotherapy pairs™ (scip) platform with kyowa kirin’s expertise in cellular therapies and underscores both companies’ commitment to using emerging cell and gene therapy technologies to develop new ways to treat. |
| 2024-10-31 02:40:00 |
|
| 2024-10-08 03:05:00 |
|
| 2024-09-19 08:00:00 |
|
| 2024-08-23 11:05:00 |
|
| 2024-08-07 03:00:00 |
|
| 2024-06-10 07:30:00 |
|
| 2024-05-08 17:30:00 |
|
| 2024-04-12 09:00:00 |
|
| 2024-04-02 13:15:00 |
|
| 2024-03-08 10:00:00 |
|
📰 Browse additional press releases for Kyowa Kirin!
Sign up for free or log in
Have you heard about our short Daily Video Newsletter?
Find out more
Frequently Asked Questions
📊 What exactly does InsightfulValue do?✖
InsightfulValue helps investors analyze public companies with smart tools, highlighting undervalued opportunities based on solid data, not hype.
🔍 How do you identify undervalued stocks?✖
We use key metrics like P/E, P/B, cash flow, debt levels, and more—blended with value-investing principles and proprietary scoring.
📈 Do you provide real-time stock data?✖
We focus on fundamental analysis and not real-time price feeds. Our data is updated regularly for financials, ratios, and risk metrics.
🧠 Do I need investing experience to use InsightfulValue?✖
Not at all. Our platform is built to be beginner-friendly while still offering advanced tools for experienced investors.
💡 What makes your analysis different?✖
We strip away the noise and show only meaningful data—SWOTs, margin of safety, 30-year financial trends, peer comparisons, and more.
💰 Is there a free version of InsightfulValue?✖
Yes! You can explore key features for free. If you want full access to all companies and premium tools, we offer an upgrade.
📚 Where do you get your financial data?✖
We use trusted financial data providers and cross-reference sources to ensure accuracy and depth.
🛠️ What kind of tools are included in premium access?✖
Premium users get advanced filters, full financial history, fair value estimations, risk flags, and investment checklists.
🔒 How secure is my data on InsightfulValue?✖
We take data privacy seriously. All information is encrypted and we never sell your personal data.
🧾 Can I use InsightfulValue for due diligence?✖
Absolutely. Our tools are designed to simplify in-depth research and help you confidently evaluate companies before investing.